| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers N > Headlines for Neurochem Inc. > News item |
Neurochem data shows Alzhemed slows Alzheimer's disease, reduces toxicity to brain cells
By Elaine Rigoli
Tampa, Fla., April 24 - Neurochem, Inc. released new data on the ongoing phase 3 clinical trial for tramiprosate (Alzhemed), its investigational product candidate for the treatment of Alzheimer's disease, that suggest ongoing clinically significant benefits on cognitive and global performance measures.
The data showed stabilization of the disease in a proportion of mild patients (four out of nine) after three years of treatment, according to a news release.
New data also shows that tramiprosate has a protective effect on neuronal cells against A(B) peptide-induced toxicity and cell death.
Tramiprosate decreases A(B)42-induced cell death and DNA damage in neuronal cell cultures by 38%, the release said.
"Overall, the Alzhemed program is very exciting. The fact that this product can reduce amyloid accumulation, a major culprit in Alzheimer's disease, and provide a protective effect against amyloid-induced toxicity to brain cells is encouraging," Paul S. Aisen, a professor of neurology and medicine at Georgetown University Medical Center and principal investigator in the trial, said in the release.
"Developing a successful treatment to slow the progression of this disease, which today remains an unmet medical need, would be a major advance in the fields of neurology and age-related illnesses."
This data was presented April 22 in Geneva, Switzerland, during the International Geneva/Springfield Symposium on Advances in Alzheimer Therapy.
Based in Laval, Quebec, Neurochem is focused on the development and commercialization of therapeutics to address unmet medical needs.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.